Back to Freepaper Session

ICL lens for correction of moderate to high ametropia: 12 month results

Session Details

Session Title: Phakic IOL Implantation II

Session Date/Time: Wednesday 09/10/2013 | 08:00-10:30

Paper Time: 09:15

Venue: E104-105 (First Floor)

First Author: : A.Leal PORTUGAL

Co Author(s): :    M. Rego   J. Luķs Silva   J. Póvoa   J. Mira   C. Lobo   J.

Abstract Details

Purpose:

To evaluate the efficacy, safety and predictability of "Intraocular Collamer Lens" (ICL) at 12 months, in the correction of moderate to high ametropia

Setting:

Department of Ophthalmology, Centro Hospitalar e Universitįrio de Coimbra, Portugal; Faculty of Medicine, University of Coimbra (FMUC), Portugal

Methods:

Retrospective study of ICL implanted in our department between June 2009 and June 2011. We evaluated the visual acuity (VA) with and without correction (BCVA and BNCVA), residual spherical equivalent (SE), endothelial cells count (ECC) pre-surgery and at 12 months, range of VA, intraocular pressure (IOP), thus as the results of a satisfaction questionnaire. The patients were divided into two groups according to the type of implanted ICL (Spherical and Toric). Of the 31 ICL implanted, 13 were spherical ICL and 18 were Toric ICL, in 19 individuals, with a mean age of 33.68 ± 3.42 years

Results:

In the spherical ICL group, the initial SE was -7.85 ± 1.92 D and 69.23% of eyes have an initial BCVA ? 0.0 LogMAR (100% ? +0.3 LogMAR). The residual SE after 1 year was -0.13 ± 0.23 D and 84.61% of eyes show a final BCVA ? 0.0 LogMAR (90.9% without correction). An eye gained 1 line and 3 eyes gained 2 lines. Any eye lost lines of BCVA. In the toric ICL group, the initial SE was -9.0 ± 2.45 D and the initial cylinder -3.18 ± 0.75 D. The initial BCVA is ? 0.0 LogMAR in 16.66% of the eyes (100% ? +0.2 LogMAR). The residual SE after 1 year was -0.14 ± 0.39 D and the residual cylinder was -0.30 ± 0.49 D; The BCVA is ? 0.0 LogMAR in 72.72% of the eyes (84.6% without correction). Three eyes gained 1 line, 5 gained 2 lines and 4 gained more than 2 lines. The average loss of EC was 6.5%. There were no side effects during the first year and all patients reported an improvement in quality of life

Conclusions:

ICL lenses for the correction of medium to high ametropia allows excellent refractive results, with possible gain in BCVA lines, being safe at 12 months. It is necessary a longer follow-up to assess the onset of late complications, including the appearance of lens anterior opacities and loss of endothelial cells

Financial Interest:

NONE